COVID Medicines Delivery Unit (CMDU) Service - Triage & Prescribing

Concepts

• health services
• service configuration st pancras programme
• prescribing
• covid
• triage
• medicines
• cmdu
• north central london integrated care board procurement oversight group
• iv treatment
• direct award process

Location

London:

Description

Every NHS region is required to provide a 7-day service including bank holidays (or 6-day service with additional administrative and on-call clinical arrangements) to enable patient contact, triage, prescribing and dispensing of oral medication or an onward referral for an infusion service (which provides prescribing, dispensing and administration of IV treatment over 7 days) to ensure patients do not miss the option of treatment within the confined treatment window of 5 days.

Total Quantity or Scope

This contract relates to the triage and prescribing element of this service. Our intention is to award a contract to an existing provider following direct award process C. The lifetime value of the contract is £549,323 (£274,661.50 per annum). The contract term will be 1 year (01/04/2025 - 31/03/2026) with the option to extend for a further 1 year (to 31/03/2027) at the sole discretion of the Authority.This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 09/04/2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.Written representations should be sent to nclicb.nclprimarycare@nhs.net. Decision Makers: North Central London Integrated Care Board Procurement Oversight Group 20/11/2024. Voting Members: Chief Finance Officer, Director of Service Configuration St Pancras Programme (deputising for Chief Strategy and Population Health Officer), Executive Director of Corporate Affairs, Director of Quality. The Register of Declarations of Interest was noted by the Procurement Oversight Group. Members were invited to amend their entries in the Register of Declarations of Interest, and to declare any interests in respect to items on the agenda. No interests were declared. The Procurement Oversight Group approved the route to market. Additional information: This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 09/04/2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.Written representations should be sent to nclicb.nclprimarycare@nhs.net. Decision Makers: North Central London Integrated Care Board Procurement Oversight Group 20/11/2024. Voting Members: Chief Finance Officer, Director of Service Configuration St Pancras Programme (deputising for Chief Strategy and Population Health Officer), Executive Director of Corporate Affairs, Director of Quality. The Register of Declarations of Interest was noted by the Procurement Oversight Group. Members were invited to amend their entries in the Register of Declarations of Interest, and to declare any interests in respect to items on the agenda. No interests were declared. The Procurement Oversight Group approved the route to market. The provider was assessed against the five key criteria: 1. quality and innovation 2. value3. integration, collaboration and service sustainability 4. improving access, reducing health inequalities and facilitating choice5. social value and was confirmed to pass them all.

Award Detail

Renewal Options

1 year extension

Award Criteria

CPV Codes

• 85100000 - Health services

Indicators

• Options are available.

Legal Justification

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to the relevant authority by 09/04/2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 09/04/2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.Written representations should be sent to nclicb.nclprimarycare@nhs.net. Decision Makers: North Central London Integrated Care Board Procurement Oversight Group 20/11/2024. Voting Members: Chief Finance Officer, Director of Service Configuration St Pancras Programme (deputising for Chief Strategy and Population Health Officer), Executive Director of Corporate Affairs, Director of Quality. The Register of Declarations of Interest was noted by the Procurement Oversight Group. Members were invited to amend their entries in the Register of Declarations of Interest, and to declare any interests in respect to items on the agenda. No interests were declared. The Procurement Oversight Group approved the route to market.